According to our information, the board of directors of Biosenic, the Franco-Belgian biotech (based in Mont-Saint-Guibert) which took over from the former Bone Therapeutics, has dismissed the deputy general director, Véronique Pomi, from her position. -Schneiter. The president and CEO, François Rieger, could also experience the same fate. This decision by the company would reflect a divergence in the development strategy of the company which is struggling to find funds to finance its various research projects to treat serious autoimmune diseases (graft versus host disease, lupus erythematosus, systemic sclerosis). The presence of the hedge fund, ABO Infinium Americas OpCo LTD, raises concerns because the operation of the latter puts Biosenic’s share price under strain. Like biotech companies, Biosenic is consuming cash for the moment; it closed 2023 with a net loss of more than 29 million euros (-3 million in 2022).
Want to read the rest of this article?
Cet article premium
is reserved for our subscribers.
Are you already a subscriber?
Log in
Not yet subscribed?
Subscribe
at L Post to promote press plurality. L-Post is not funded by any major group and relies solely on readers. Informing with rigor and independence has a cost.
Support L Post and independent journalism: BE85 0689 4115 0106
Related News :